Hormonal
Therapeutic CPAP does not significantly improve glycaemic control (HbA1c) or insulin resistance (measured by euglycaemic clamp and HOMA) in men with established type 2 diabetes and obstructive sleep apnoea.
If you have type 2 diabetes and sleep apnoea, using CPAP will help you feel less sleepy and improve your quality of life, but it will not lower your blood sugar or fix insulin resistance on its own. You still need to manage your diabetes with diet, medication, or other treatments specifically designed for metabolic control.
Therapeutic CPAP does not significantly improve measures of glycaemic control or insulin resistance in men with type 2 diabetes and OSA.
Why this rating
The study is a double-blind, randomized controlled trial with a placebo control group, which is the gold standard for establishing causality and ruling out confounders.
Source
Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes
Sophie West et al. · Thorax · 2007
DOI 10.1136/thx.2006.074351
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →